At Oslo University Hospital (OUH), patients receive a broad range of radionuclide therapies—both as part of routine clinical care and within the framework of clinical trials in which OUH either run or is actively involved. To support ongoing research and improve future patient care, we have established RNTreg OUS, a dedicated patient registry for individuals receiving radionuclide therapy at OUH, or currently being monitored by the hospital following such treatment.
The registry was launched in March 2025, with the first patient enrolled that same month. We are now working to compile retrospective data from the past ten years while continuing to include current and future patients.
Our goal is to make this registry a valuable resource for the research community—facilitating data-driven insights that can enhance understanding, treatment outcomes, and the development of therapy strategies.
Last updated: 5/19/2025, 8:32:42 AM
The patient registry currently includes 71 patients.
If you are interested in accessing data from RNTreg OUS for research or other purposes, please contact Johan Blakkisrud, Caroline Stokke or Eivor Hernes.
Researchers interested in using data from RNTreg OUS are welcome to apply. Access requires an approved project protocol and relevant ethical approvals.
Requests are reviewed by the registry’s advisory board to ensure compliance with regulations and data protection requirements.
International collaboration is possible when appropriate approvals are in place.
More information is available upon request.